Starting
Initialising…
0%
MBD4
Final classification
Likely Benign
MBD4 c.89C>T · p.Pro30Leu
MBD4

NM_003925.3:c.89C>T (p.Pro30Leu) is a missense variant in MBD4, a gene in which germline loss-of-function variants cause a multi-tumor predisposition syndrome.

Gene
MBD4
Transcript
NM_003925.3
HGVS · transcript:coding
NM_003925.3:c.89C>T
Consequence
N/A
GRCh38
chr3:129439745 G>A
GRCh37
chr3:129158588 G>A
Basis gene-specific framework lacked a usable explicit final combination framework, so generic ACMG/AMP 2015 final-combination rules were applied as fallback; applied criteria: PM2 supporting, BP1 supporting benign, BP4 supporting benign; combination = 1 supporting + 2 supporting benign, which maps to Likely Benign.
gene-specific framework lacked a usable explicit final combination framework, so generic ACMG/AMP 2015 final-combination rules were applied as fallback; applied criteria: PM2 supporting, BP1 supporting benign, BP4 supporting benign; combination = 1 supporting + 2 supporting benign, which maps to Likely Benign.
Classification rationale
PM2 BP1BP4 Likely Benign
MBD4 c.89C>T

NM_003925.3:c.89C>T (p.Pro30Leu) is a missense variant in MBD4, a gene in which germline loss-of-function variants cause a multi-tumor predisposition syndrome.1 This variant is extremely rare in population databases: absent from gnomAD v2.1 and gnomAD-Canada, and observed at an allele frequency of 6.28e-07 (1/1,593,284 alleles) in gnomAD v4.1, meeting PM2 at supporting strength.2 MBD4 germline disease is driven by loss-of-function via truncating variants; missense variants in this gene context meet BP1 at supporting benign strength. Multiple orthogonal in silico predictors concordantly predict a benign effect: REVEL score 0.016, BayesDel score -0.660, and SpliceAI max delta 0.00, meeting BP4 at supporting benign strength.3 Applying generic ACMG/AMP 2015 final classification rules (PMID:25741868): two supporting benign criteria (BP1, BP4) are met versus one supporting pathogenic criterion (PM2). The weight of evidence favors a likely benign classification.4

PM2 + BP1 + BP4 Likely Benign
1 pvs1_gene_context
3 revelbayesdelspliceai ↗
4 generic_acmg_combination_rules
Gene diagram · NM_003925.3 · variants mapped to exon structure
MBD4 NM_003925.3
Fetching transcript structure from UCSC…
Applied criteria · 3 met · select any tile
Met
Not met
Not assessed
N/A
Strength very strong supporting
Pathogenic evidence
PVS
PS
PM
PP
Benign evidence
BA
BS
BP
Rationale
Select a criterion.
Sources
Evidence used
    Gaps remaining
      Rule
      Research & evidence
      Population frequency · supports benign
      gnomAD v4.1 screenshot
      gnomAD v4.1
      gnomAD v2.1 screenshot
      gnomAD v2.1
      v4.1
      This variant is present in gnomAD v4.1 (AF= 6.27634e-07; MAF= 0.00006%, 1/1593284 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 8.54609e-07; MAF= 0.00009%, 1/1170126 alleles, homozygotes = 0).
      v2.1
      Absent from gnomAD v2.1.
      🇨🇦 CA
      Absent from gnomAD-Canada v1.0.
      Allele frequency by ancestry
      three datasets · side by side
      gnomAD v4.1
      6.3e-05% · 1 / 1,593,284
      0 hom
      European (non-Finnish)
      1 / 1,170,126
      8.5e-05%
      + 9 not observed (Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American)
      gnomAD v2.1
      Absent · 0 / ?
      0 hom
      Not observed in any ancestry group.
      gnomAD Canada 🇨🇦
      Absent · 0 / ?
      0 hom
      Not observed in any ancestry group.
      ClinVar screenshot
      ClinVar
      This variant is absent from ClinVar.
      SpliceAI screenshot
      In silico
      SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.016. BayesDel score = -0.65999.
      Functional / OncoKB screenshot
      Functional Unknown Oncogenic Effect
      OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. MBD4, a DNA glycosylase, is infrequently altered in cancer.
      OncoKB ↗
      COSMIC screenshot
      COSMIC
      Cancer hotspots screenshot
      Cancer hotspots
      Somatic evidence Not in COSMIC / hotspots
      COSMIC
      This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).
      Hotspots
      This variant does not lie in a statistically significant hotspot.
      Sources & reference links
      8Sources
      ClinVar
      gnomAD v2.1
      gnomAD v4.1
      gnomAD-Canada
      SpliceAI
      OncoKB
      COSMIC
      Cancer hotspots